Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2008

View Archived Issues

BrainStorm reports results from rat study of NTF cells in Parkinson's disease

Novartis pays USD 25 million milestone payment to Antisoma in relation to ASA-404

4SC acquires stake in Nexigen and enters licensing agreement with ViroLogik

InSite signs Chinese licensing agreement with Essex Biotechnology for AzaSite

Human Genome Sciences presents an update on clinical development portfolio

Gene therapy for retinal albinism presented at the ASGT meeting

Murine von Willebrand disease ameliorated by helper-dependent adenovirus gene transfer

Boehringer Ingelheim gets first approval within E.U. for Actilyse

Antiinflammatory compound ND-07 improves experimental acute pancreatitis

Bristol-Myers Squibb to acquire cancer therapeutics company, Kosan Biosciences

FDA grants fast track to Wyeth's 13-valent pneumococcal conjugate vaccine

IntelGenx presents positive results from pilot pharmacokinetic study on CPI-300

Lipoxen reports phase I data for long-acting insulin candidate, SuliXen

SymBio completes enrollment in phase II study in indolent non-Hodgkin's lymphoma

Triphendiol safe in phase Ia pharmacokinetic study

Wyeth receives FDA approvable letter for Tygacil in community-acquired pneumonia

Phase I data show activity of NKTR-102 in solid tumor patients

Camurus reports positive phase II results for CAM-2028 in oral mucositis pain

Human Genome Sciences has initiated dosing in phase I HGS-1029

Novel antiinfective agents disclosed in recent GSK patents

Novel anti-HIV agents reported in recent patents

Nisshin Kyorin patent describes new therapeutic options for IBD

Genmab announces completion of pivotal phase III trial of ofatumumab in CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...